EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Vitamin Sources: 15

Nicotinamide riboside

Also called: NR, nicotinamide riboside chloride

Nicotinamide riboside (NR) is a member of the vitamin B3 family and a precursor of the coenzyme NAD+. Supplements usually contain a crystalline form, nicotinamide riboside chloride.

Category
Vitamin
Forms
Nicotinamide riboside chloride (oral)
Strongest evidence
C Limited
Reviewed
2026-10-28

Class 1 Well studied in people. No review stating a count of NR-alone trials was found. This entry cites 11 RCTs of nicotinamide riboside alone: oral NR versus placebo, 2018-2026; one trial also had an NR-plus-resveratrol arm. [2]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied4 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Nicotinamide riboside does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Nicotinamide riboside, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Blood NAD+ levelsCIn an 8-week randomized trial in overweight adults, 100, 300 and 1,000 mg/day raised whole-blood NAD+ by 22%, 51% and 142% within 2 weeks. This is a biomarker, not a health outcome. [1]
Insulin sensitivity in obese, insulin-resistant menXA 12-week randomized trial in 40 men (2,000 mg/day) found no improvement in clamp-measured insulin sensitivity, glucose metabolism, energy expenditure or body composition. [2]
Walking distance in peripheral artery diseaseCA randomized trial in 90 people found NR improved 6-minute walk distance at 6 months versus placebo (between-group difference +17.6 m); a larger trial is needed to confirm this. [3]
Muscle mass and function in adults over 60CA meta-analysis concluded current evidence does not support NR or NMN for preserving muscle mass and function; in people with mild cognitive impairment, some physical scores were lower with NR. [4]
Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • 100, 300 or 1,000 mg/day for 8 weeks in overweight adults. [1]
  • 1,000 mg twice daily (2,000 mg/day) for 12 weeks in obese men. [2]

Upper limits

  • EU: EFSA concluded nicotinamide riboside chloride is safe as a novel food at up to 300 mg/day for healthy adults (excluding pregnancy and lactation) and up to 230 mg/day for pregnant and lactating women. [5]
Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    EFSA (2019) concluded the novel food is safe at the proposed uses for the healthy adult population excluding pregnant and lactating women, and that …

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    6 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • In the 8-week trial there was no flushing, no difference in adverse events from placebo, and no rise in LDL cholesterol. [1]
  • At 2,000 mg/day for 12 weeks there were no serious adverse events and safety blood tests were normal. [2]
Regulation

Regulatory status

  • US: FDA had no questions about GRAS Notice 635 for nicotinamide riboside chloride as a source of vitamin B3 in certain foods and beverages (closed August 3, 2016). This concerns food use, not supplements. [6]
  • US: FDA states that, by law, it does not approve dietary supplements or their labeling before they are marketed; firms are responsible for the safety and labeling of their products. [7]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Nicotinamide riboside (supplied as the chloride and other salts) NAD+ precursor vitamin [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 6 entries naming nicotinamide riboside (earliest NDI 882 submitted 2015-08-24; most recent NDI 1420 submitted 2025-07-11), covering the chloride, hydrogen malate and citrate forms. Each entry is one party's notification; the list gives the date of FDA's response letter but not what it said. [P5]
  • US: FDA had no questions about GRAS Notice 635 for nicotinamide riboside chloride as a source of vitamin B3 in certain foods and beverages (closed August 3, 2016). This concerns food use, not supplements. [P4]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC carcinogenicity evaluation of nicotinamide riboside was found (IARC Monographs list of classifications checked 2026-10-29). [P6]
  • No NTP technical report on nicotinamide riboside was found (NTP technical reports list checked 2026-10-29). [P7]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination of each component that is a dietary ingredient, before use — Required by 21 CFR 111.75(a)(1)(i); a manufacturer may petition for an exemption from this testing under 111.75(a)(1)(ii). [P8]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • First human PK trial: single oral doses of 100, 300 and 1,000 mg NR produced dose-dependent increases in the blood NAD+ metabolome; nicotinic acid adenine dinucleotide (NAAD) rose and was proposed as a sensitive biomarker. [P1]
  • 8-week RCT in healthy overweight adults: 100, 300 and 1,000 mg/day NR increased whole-blood NAD+ by 22%, 51% and 142% within 2 weeks, maintained to study end. [P2]
  • EFSA concluded that nicotinamide riboside chloride is a source from which nicotinamide, a form of niacin, is bioavailable. [P3]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • EFSA (2019) concluded the novel food is safe at the proposed uses for the healthy adult population excluding pregnant and lactating women, and that intakes up to 230 mg/day are safe for pregnant and lactating women. [P3]

Sources for this profile

  1. Trammell SA, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun 2016;7:12948 (PMID 27721479; authors include employees and shareholders of the NR supplier), 2016-10-10. pubmed.ncbi.nlm.nih.gov
  2. Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep 2019;9:9772 (PMID 31278280; study funded by the NR supplier), 2019-07-05. pubmed.ncbi.nlm.nih.gov
  3. EFSA NDA Panel. Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source. EFSA Journal 2019;17(8):5775, 2019-08. efsa.europa.eu
  4. U.S. FDA. GRAS Notice Inventory: GRN No. 635, nicotinamide riboside chloride, 2016-08-03. hfpappexternal.fda.gov
  5. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  6. IARC Monographs. List of Classifications (accessed October 29, 2026), 2026-10-29. monographs.iarc.who.int
  7. National Toxicology Program. Technical Reports (TR) list (accessed October 29, 2026), 2026-10-29. ntp.niehs.nih.gov
  8. eCFR. 21 CFR 111.75 (title 21 displayed up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources

Sources

  1. Conze D, Brenner C, Kruger CL. Safety and metabolism of long-term administration of NIAGEN (nicotinamide riboside chloride) in a randomized, double-blind, placebo-controlled clinical trial of healthy overweight adults. Sci Rep 2019;9:9772 (PMID 31278280; authors include company scientists), 2019-07-05. pubmed.ncbi.nlm.nih.gov
  2. Dollerup OL, et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 2018;108(2):343-353 (PMID 29992272), 2018-08-01. pubmed.ncbi.nlm.nih.gov
  3. McDermott MM, et al. Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial. Nat Commun 2024;15:5046 (PMID 38871717), 2024-06-13. pubmed.ncbi.nlm.nih.gov
  4. Prokopidis K, et al. The effect of nicotinamide mononucleotide and riboside on skeletal muscle mass and function: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2025;16(3):e13799 (PMID 40275690), 2025-06. pubmed.ncbi.nlm.nih.gov
  5. EFSA NDA Panel. Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source. EFSA Journal 2019;17(8):5775, 2019-08. efsa.europa.eu
  6. U.S. FDA. GRAS Notice Inventory: GRN No. 635, nicotinamide riboside chloride, 2016-08-03. hfpappexternal.fda.gov
  7. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
  8. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 2018;9(1):1286 (PMID 29599478), 2018-03-29. pubmed.ncbi.nlm.nih.gov
  9. Remie CME, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am J Clin Nutr 2020;112(2):413-426 (PMID 32320006), 2020-08-01. pubmed.ncbi.nlm.nih.gov
  10. Brakedal B, et al. The NADPARK study: a randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease. Cell Metab 2022;34(3):396-407.e6 (PMID 35235774), 2022-03-01. pubmed.ncbi.nlm.nih.gov
  11. Berven H, et al. NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. Nat Commun 2023;14(1):7793 (PMID 38016950), 2023-11-28. pubmed.ncbi.nlm.nih.gov
  12. Orr ME, et al. A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. Geroscience 2024;46(1):665-682 (PMID 37994989), 2023-11-23. pubmed.ncbi.nlm.nih.gov
  13. Norheim KL, et al. Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial. Nat Aging 2024;4(12):1772-1781 (PMID 39548320), 2024-11-15. pubmed.ncbi.nlm.nih.gov
  14. Shoji M, et al. Nicotinamide riboside supplementation benefits in patients with Werner syndrome: a double-blind randomized crossover placebo-controlled trial. Aging Cell 2025;24(8):e70093 (PMID 40459998), 2025-06-03. pubmed.ncbi.nlm.nih.gov
  15. Martens CR, et al. A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment. Alzheimers Dement 2026;22(7):e71605 (PMID 42478598), 2026-07. pubmed.ncbi.nlm.nih.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in vitamin: Benfotiamine · Biotin · Folate (folic acid) · Methylfolate (L-5-MTHF) · Niacin (vitamin B3) · Pantothenic acid (vitamin B5) · Riboflavin (vitamin B2) · Thiamin (vitamin B1) · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.